查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1542758

C反应蛋白检测的全球市场

C-Reactive Protein Testing
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 244 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

到 2030 年，全球 C 反应蛋白检测市场将达到 32 亿美元

全球 C 反应蛋白检测市场预计 2023 年为 29 亿美元，预计到 2030 年将达到 32 亿美元，2023 年至 2030 年复合年增长率为 1.8%。心血管疾病的 C 反应蛋白检测是本报告分析的细分市场之一，预计复合年增长率为 2.6%，到分析期结束时将达到 9.553 亿美元。分析期间，癌症疾病领域 C 反应蛋白检测的复合年增长率估计为 2.1%。

美国市场预估为8.441亿美元，中国预期复合年增长率为1.7%

预计 2023 年美国C 反应蛋白检测市场规模将达 8.441 亿美元。中国作为全球第二大经济体，预计2030年市场规模将达5.81亿美元，2023年至2030年复合年增长率为1.7%。其他值得注意的区域市场包括日本和加拿大，在分析期间预计复合年增长率分别为 1.7% 和 1.3%。在欧洲，德国的复合年增长率预计为 1.9%。

全球 C 反应蛋白检测市场 - 主要趋势和驱动因素总结

除了发炎之外，C 反应蛋白检测对美国意味着什么？

C 反应蛋白 (CRP) 测试是一种广泛使用的诊断工具，旨在测量 CRP 的血液水平，CRP 是肝臟响应发炎而产生的一种蛋白质。 CRP 的存在与多种疾病有关，从急性感染疾病到慢性疾病和自体免疫疾病。透过测量 CRP 水平，医疗保健提供者可以评估体内是否存在发炎、确定其严重程度并监测治疗效果。该测试特别有价值，因为它可以区分通常导致 CRP 升高的细菌和病毒感染，并有助于指南类风湿性关节炎和克隆氏症等慢性发炎疾病的治疗。

科技如何提高 CRP 测试的准确性和可近性？

医疗技术的进步显着提高了 CRP 检测的准确性和效用。最新的 CRP 测试可以在几分钟内提供结果，从而实现快速的临床决策。可直接在病人床边或检查室使用的护理点 CRP 测试设备尤其具有创新性。无需将样本送到实验室，等待结果的时间也减少了。此外，微流体和生物感测技术的最新趋势导致了更小、更灵敏的 CRP 测试设备的开发，这些设备仅需要少量的血液样本。

实施 CRP 测试有哪些挑战？

儘管有许多好处，但实施 CRP 测试仍面临一些挑战。主要问题之一是，在 CRP 值无法提供明确的诊断资讯的情况下，该测试可能会被过度使用或误用。对 CRP 结果的误解可能会导致不必要的治疗，包括不当地使用抗生素来治疗病毒感染。此外，虽然护理点 CRP 测试提供了便利，但确保这些设备在所有医疗保健环境中的准确性和可靠性也很重要，但也存在许多挑战。培训医疗保健提供者了解 CRP 测试结果并将其有效地融入临床实践对于最大限度地发挥 CRP 测试的好处并避免潜在的缺点也至关重要。

推动CRP检测市场扩大的主要因素有哪些？

C反应蛋白检测市场的成长受到多种因素的推动。心血管疾病、类风湿性关节炎和发炎性肠道疾病等发炎疾病的盛行率不断增加，增加了对 CRP 检测等有效诊断和监测工具的需求。医生和患者对发炎重要性及其在各种健康状况中的作用的认识不断提高也促进了这一趋势。此外，护理点诊断的扩展以及经济实惠且快速的 CRP 检测设备的出现，使得这些检测更容易为更多人群所接受。随着医疗保健系统继续强调预防性护理和早期疗育，CRP 检测被定位为宝贵的医学武器库，推动了不同医疗保健环境中的采用和市场成长。

受访企业范例（43家知名企业）

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings（LabCorp）
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

目录

第一章调查方法

第 2 章执行摘要

  • 市场概况
  • 主要企业
  • 市场趋势和驱动因素
  • 全球市场展望

第三章市场分析

  • 美国
  • 加拿大
  • 日本
  • 中国
  • 欧洲
  • 法国
  • 德国
  • 义大利
  • 英国
  • 其他欧洲国家
  • 亚太地区
  • 其他领域

第四章 比赛

简介目录
Product Code: MCP11362

Global C-Reactive Protein Testing Market to Reach US$3.2 Billion by 2030

The global market for C-Reactive Protein Testing estimated at US$2.9 Billion in the year 2023, is expected to reach US$3.2 Billion by 2030, growing at a CAGR of 1.8% over the analysis period 2023-2030. C-Reactive Protein Testing for Cardiovascular Diseases, one of the segments analyzed in the report, is expected to record a 2.6% CAGR and reach US$955.3 Million by the end of the analysis period. Growth in the C-Reactive Protein Testing for Cancer Disease segment is estimated at 2.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$844.1 Million While China is Forecast to Grow at 1.7% CAGR

The C-Reactive Protein Testing market in the U.S. is estimated at US$844.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$581.0 Million by the year 2030 trailing a CAGR of 1.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.7% and 1.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.9% CAGR.

Global C-Reactive Protein Testing Market - Key Trends and Drivers Summarized

Beyond Inflammation: What Can C-Reactive Protein Testing Really Tell Us?

C-reactive protein (CRP) testing is a widely used diagnostic tool designed to measure the level of CRP in the blood, a protein produced by the liver in response to inflammation. The presence of CRP is associated with a variety of conditions, from acute infections to chronic diseases and autoimmune disorders. By measuring CRP levels, healthcare providers can assess if there is an inflammation in the body, determine its severity, and monitor the effectiveness of treatment. This test is particularly valuable because it can help distinguish between bacterial infections, which typically cause a higher CRP elevation, and viral infections, alongside guiding therapy in chronic inflammatory conditions like rheumatoid arthritis and Crohn's disease.

How Is Technology Enhancing CRP Testing Accuracy and Accessibility?

The accuracy and utility of CRP testing have significantly improved with advancements in medical technology. Modern CRP tests can deliver results in a matter of minutes, allowing for rapid clinical decision-making. Point-of-care CRP testing devices, which can be used directly at the patient’s bedside or in the doctor's office, are particularly revolutionary. They eliminate the need to send samples to a lab and reduce the waiting time for results. Moreover, recent developments in microfluidics and biosensing technologies have led to the creation of even smaller, more sensitive CRP testing devices that require only a tiny blood sample, making the test less invasive and more comfortable for patients.

What Challenges Are Faced in the Implementation of CRP Testing?

Despite its benefits, the implementation of CRP testing faces certain challenges. One of the primary concerns is the potential for overuse or misuse of the test, particularly in situations where CRP levels may not provide definitive diagnostic information. Misinterpretation of CRP results can lead to unnecessary treatments, such as the inappropriate use of antibiotics for viral infections. Additionally, while point-of-care CRP testing offers convenience, ensuring the accuracy and reliability of these devices across all healthcare settings is critical but challenging. Training healthcare providers to understand and integrate CRP test results effectively into the clinical context is also essential to maximize the test's benefits and avoid potential drawbacks.

What Key Factors Are Fueling the Expansion of the CRP Testing Market?

The growth in the C-Reactive Protein testing market is driven by several factors. The rising prevalence of inflammatory diseases such as cardiovascular disorders, rheumatoid arthritis, and inflammatory bowel disease has led to an increased demand for effective diagnostic and monitoring tools like CRP testing. Growing awareness among physicians and patients about the importance of inflammation and its role in various health conditions also contributes to this trend. Additionally, the expansion of point-of-care diagnostics and the increasing availability of affordable and rapid CRP testing devices have made these tests more accessible to a broader segment of the population. As health systems continue to emphasize preventive care and early intervention, CRP testing is positioned as a valuable tool in the medical arsenal, promoting its adoption and market growth across diverse healthcare environments.

Select Competitors (Total 43 Featured) -

  • Abaxis, Inc.
  • Abbott Laboratories
  • Danaher Corporation
  • F. Hoffmann-La Roche AG
  • Laboratory Corporation of America Holdings (LabCorp)
  • Merck KgaA
  • Quest Diagnostics, Inc.
  • Randox Laboratories Ltd.
  • Siemens Healthineers
  • Thermo Fisher Scientific, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • C-Reactive Protein Testing - Global Key Competitors Percentage Market Share in 2024 (E)
    • Impact of COVID-19 Pandemic and Looming Global Recession
    • What is C-reactive Protein (CRP)?
    • An Introduction to C-reactive Protein Testing
    • Global Market Prospects & Outlook
    • Immunoturbidimetric Assays: The Major Segment by Assay Type
    • hs-CRP Test Type Leads by Detection Range
    • Cardiovascular Diseases Emerge As the Leading Disease Type for CRP Testing, Cancer Detection to Make Strong Gains
    • Clinics & Hospitals Hold Dominant Share of CRP Testing Market
    • Developed Regions Lead, Developing Economies to Spur Market Growth
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prominence of POC Testing Approaches for C-reactive Protein Testing Enable Faster and Accurate Results
    • CRP Testing for Ascertaining Viral Infections
    • Growing Incidence of HIV Infections and Need for Monitoring of HIV Diseases Drive CRP Testing
    • Threat of Endometriosis in Women: Significant Role of CRP Testing
    • CRP Testing: A Vital Diagnostic Tool for Cancer
    • CRP Testing Holds Potential Role in Assessing Effectiveness of Antibiotic Drugs
    • Funding Support for Extensive Research on Applications of C-reactive Protein Testing to Boost Market Growth
    • Growing Use of CRP Testing in Cardiovascular Risk Assessment Bolsters Market Growth
    • Integration of CRP Testing in Routine Check-ups Enhances Early Detection Rates
    • Research Linking Inflammation to Various Chronic Diseases Strengthens Test Demand
    • Emerging Markets Offer Significant Opportunities Due to Expanding Healthcare Systems
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Recent Past, Current & Future Analysis for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 2: World Historic Review for Cardiovascular Diseases by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 3: World 16-Year Perspective for Cardiovascular Diseases by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 5: World Historic Review for Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 6: World 16-Year Perspective for Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 7: World Recent Past, Current & Future Analysis for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 8: World Historic Review for Rheumatoid Arthritis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 9: World 16-Year Perspective for Rheumatoid Arthritis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 11: World Historic Review for Inflammatory Bowel Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 12: World 16-Year Perspective for Inflammatory Bowel Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 13: World Recent Past, Current & Future Analysis for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 14: World Historic Review for Endometriosis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 15: World 16-Year Perspective for Endometriosis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 17: World Historic Review for Lupus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 18: World 16-Year Perspective for Lupus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 19: World Recent Past, Current & Future Analysis for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 20: World Historic Review for Other Disease Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 21: World 16-Year Perspective for Other Disease Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 22: World Recent Past, Current & Future Analysis for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 23: World Historic Review for Immunoturbidimetric Assay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 24: World 16-Year Perspective for Immunoturbidimetric Assay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 25: World Recent Past, Current & Future Analysis for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 26: World Historic Review for ELISA by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 27: World 16-Year Perspective for ELISA by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 28: World Recent Past, Current & Future Analysis for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 29: World Historic Review for Chemiluminescence Immunoassay by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 30: World 16-Year Perspective for Chemiluminescence Immunoassay by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 31: World Recent Past, Current & Future Analysis for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 32: World Historic Review for Other Assay Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 33: World 16-Year Perspective for Other Assay Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 34: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 35: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 36: World 16-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 37: World Recent Past, Current & Future Analysis for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 38: World Historic Review for Laboratories by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 39: World 16-Year Perspective for Laboratories by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 40: World Recent Past, Current & Future Analysis for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 41: World Historic Review for Clinics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 42: World 16-Year Perspective for Clinics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 43: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 44: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 45: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 46: World C-Reactive Protein Testing Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 47: World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 48: World Historic Review for C-Reactive Protein Testing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: World 16-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 50: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: USA 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: USA 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 56: USA Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: USA Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: USA 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 59: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Canada 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Canada 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 65: Canada Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Canada Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Canada 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • JAPAN
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 68: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Japan 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: Japan 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 74: Japan Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: Japan Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: Japan 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • CHINA
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 77: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: China Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: China 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: China Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: China 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 83: China Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: China Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: China 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • EUROPE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 86: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Europe 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Europe 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Europe 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
    • TABLE 95: Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 96: Europe Historic Review for C-Reactive Protein Testing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Europe 16-Year Perspective for C-Reactive Protein Testing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
  • FRANCE
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 98: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: France Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: France 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: France Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: France 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 104: France Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: France Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: France 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • GERMANY
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 107: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Germany 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Germany 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 113: Germany Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Germany Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Germany 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 116: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Italy 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Italy 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 122: Italy Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Italy Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Italy 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 125: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: UK 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: UK 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 131: UK Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: UK Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: UK 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 135: Rest of Europe Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 136: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 138: Rest of Europe Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 139: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 142: Rest of Europe 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • C-Reactive Protein Testing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 144: Asia-Pacific Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 145: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 147: Asia-Pacific Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 148: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 151: Asia-Pacific 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 152: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 153: Rest of World Historic Review for C-Reactive Protein Testing by Disease Type - Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 154: Rest of World 16-Year Perspective for C-Reactive Protein Testing by Disease Type - Percentage Breakdown of Value Sales for Cardiovascular Diseases, Cancer, Rheumatoid Arthritis, Inflammatory Bowel Disease, Endometriosis, Lupus and Other Disease Types for the Years 2014, 2024 & 2030
    • TABLE 155: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 156: Rest of World Historic Review for C-Reactive Protein Testing by Assay Type - Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 157: Rest of World 16-Year Perspective for C-Reactive Protein Testing by Assay Type - Percentage Breakdown of Value Sales for Immunoturbidimetric Assay, ELISA, Chemiluminescence Immunoassay and Other Assay Types for the Years 2014, 2024 & 2030
    • TABLE 158: Rest of World Recent Past, Current & Future Analysis for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 159: Rest of World Historic Review for C-Reactive Protein Testing by End-Use - Hospitals, Laboratories, Clinics and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 160: Rest of World 16-Year Perspective for C-Reactive Protein Testing by End-Use - Percentage Breakdown of Value Sales for Hospitals, Laboratories, Clinics and Other End-Uses for the Years 2014, 2024 & 2030

IV. COMPETITION